Sanofi Reports Double-Digit Q3 Sales and EPS Growth, Upgrades Full-Year 2026 Guidance

Sanofi announced a strong third quarter in 2026, with sales growing 14.3% at constant exchange rates (CER) and business earnings per share (EPS) increasing by 19.6% at CER to €3.55. The company's pharmaceutical launches, including ALTUVIIIO, Ayvakit, and Rezurock, contributed significantly with a 31.4% sales increase to €1.4 billion, while Dupixent sales rose 34.8% to €5.7 billion. Following these results, Sanofi has upgraded its full-year 2026 guidance, now expecting sales to grow by a low-teens percentage at CER and business EPS to increase by a mid-teens percentage at CER.